Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma
Webcast
1 AMA PRA Category 1 Credit™ ...OVERVIEW
Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma is organized by Global Oncology Academy (GOA).
Publication Dates
Release Date: 03/01/2024
Expiration Date: 03/01/2025
Description:
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
Learning Objectives:
After participating in this educational activity, participants should be better able to:
- Identify patients with relapsed and refractory multiple myeloma (RRMM) who are eligible to receive treatment with a bispecific antibody
- Differentiate between bispecific antibodies that are FDA-approved for the treatment of RRMM
- Recognize the adverse event profile of bispecific antibodies used for the treatment of RRMM
- Employ strategies to prevent adverse events associated with bispecific antibody treatment for RRMM, including prophylaxis and step-up dosing, into treatment planning
ACCREDITATION & CREDITS
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until March 1, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour/0.1 CEUs of pharmacy contact hours.1
TARGET AUDIENCE
PhysicianPharmacistEmergency Medicine PhysiciansOncologistsHospitalistHematologistPathologistsAdvanced Practice ProvidersSPECIALITIES
OncologyHematology
Quick Links